Lenalidomide and R-CHOP in B-cell Lymphoma

Mantle Cell Lymphoma Clinical Trial

— R2CHOP-1  

Official title:

A Phase IB Study of Escalating Doses of REVLIMID in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00901615
• Other study ID #: R2CHOP-1
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: January 6, 2009
• Est. completion date: November 23, 2015

Study information

• Verified date: August 2018
• Source: Lymphoma Study Association
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid) when administered in association with R-CHOP (rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone).

Description:

The study is a dose escalation study of lenalidomide (Revlimid) administered orally during 14 days in combination with fixed doses of rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks (R-CHOP 21) in patients with B-cell lymphoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 108
• Est. completion date: November 23, 2015
• Est. primary completion date: November 19, 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with one of the following B-cell Lymphoma, CD 20 positive:

• Mantle cell, Marginal zone, follicular

• Histological transformation from low grade to high grade

• Diffuse large B cell

• Aged from 18 to 70 years

• WHO performance status 0, 1 or 2

• Signed inform consent

• Life expectancy of = 90 days (3 months).

• Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL not more than 3 days from the start of study drug and must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control, at least 4 weeks before she starts taking lenalidomide. FCBP must also agree to monthly pregnancy testing and must be counseled at a minimum of every 4 weeks about pregnancy precautions and risks of fetal exposure.

• Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential. Men must also be counseled at a minimum of every 4 weeks about pregnancy precautions and risks of fetal exposure.

• † A female patient is considered to have childbearing potential unless she meets at least one of the following criteria 1) Age > 50 years and naturally amenorrhoeic for > 1 year (amenorrhoea following cancer therapy does not rule out childbearing potential); or 2) Premature ovarian failure confirmed by a specialist gynaecologist or 3) Previous bilateral salpingo-oophorectomy, or hysterectomy, or 4) XY genotype, turner syndrome, uterine agenesis.

Exclusion Criteria:

• Previous treatment with immunotherapy or chemotherapy except:

• Chlorambucil or Cyclophosphamide per os alone during less than 6 months, if stopped more than one year before inclusion

• Rituximab alone during less than three months, if stopped more than one year before inclusion

• Previous radiotherapy except if localized to one lymph node area

• Other type of lymphomas: Burkitt, T cell, lymphocytic, CD 20 negative

• Central nervous system or meningeal involvement

• Contraindication to any drug contained in the chemotherapy regimen

• HIV disease, active hepatitis B or C

• Any serious active disease or co-morbid medical condition (according to investigator's decision)

• Any of the following laboratory abnormalities :

• Absolute neutrophil count (ANC) < 1,500 cells/mm3 (1.5 x 109/L).

• Platelet count < 100,000/mm3 (100 x 109/L).

• Serum SGOT/AST or SGPT/ALT 5.0 x upper limit of normal (ULN).

• Serum total bilirubin > 2.0 mg/dL (34 µmol/L), except in case of hemolytic anemia.

• Calculated creatinine clearance (Cockcroft-Gault formula) of < 50 mL /min

• Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for = 3 years

• Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.

• Pregnant or lactating females.

• Prior = Grade 3 allergic reaction/hypersensitivity to thalidomide.

• Prior = Grade 3 rash or any desquamating (blistering) rash while taking thalidomide.

• Subjects with = Grade 2 neuropathy.

• Prior use of lenalidomide.

• Use of any standard or experimental anti-cancer drug therapy within 28 days of the initiation (Day 1) of study drug therapy.

Related Conditions & MeSH terms

• Follicular Lymphoma
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, B-Cell, Marginal Zone
• Lymphoma, Follicular
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Mantle-Cell
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma

Intervention

Drug:
• Lenalidomide and R-CHOP
Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.

Locations

Country	Name	City	State
France	CHU de Dijon	Dijon
France	CHRU Lille	Lille
France	CHU Lyon Sud	Pierre Benite
France	Centre Henri Becquerel	Rouen
France	CHU Brabois	Vandoeuvre les Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Lymphoma Study Association

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Dose Limiting Toxicities		42 days
Secondary	Complete response rate and Overall response rate at the end of treatment		3 months after the end of treatment
Secondary	Complete and Overall response rates after induction		at the end of third cycle of treatment (between Day 56 and Day 63)
Secondary	Progression-Free Survival and Overall survival		7 years
Secondary	Duration of response		7 years
Secondary	Collection of adverse events		6 months

External Links

•   GELA